August 9, 2016
Single-agent Opdivo (nivolumab) missed the primary endpoint in a key PIII trial for patients with previously untreated advanced non-small cell lung cancer (NSCLC), which included Japanese, according to top-line data released by Bristol-Myers Squibb. In the trial dubbed CheckMate-026, the...read more